B-701

DRUG2 trials

Sponsors

Mark Pomerantz, MD, Rainier Therapeutics

Conditions

Bladder CancerLocally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases

Phase 1

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

TerminatedNCT02925533

Mark Pomerantz, MDBladder Cancer

Start: 2016-12-14End: 2017-06-30Updated: 2017-06-27

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

TerminatedNCT03123055

Rainier TherapeuticsLocally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases

Start: 2017-04-20End: 2019-12-01Updated: 2020-03-18

Related Papers

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

JNCI Cancer Spectrum2024-04-166 citations

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Journal of Clinical Oncology2019-05-2064 citations